Symbols / ARDX
ARDX Chart
About
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.60B |
| Enterprise Value | 1.58B | Income | -61.60M | Sales | 407.32M |
| Book/sh | 0.68 | Cash/sh | 1.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | 489 | IPO | — |
| P/E | — | Forward P/E | 12.04 | PEG | — |
| P/S | 3.92 | P/B | 9.62 | P/C | — |
| EV/EBITDA | -41.62 | EV/Sales | 3.87 | Quick Ratio | 3.80 |
| Current Ratio | 4.32 | Debt/Eq | 140.06 | LT Debt/Eq | — |
| EPS (ttm) | -0.23 | EPS next Y | 0.55 | EPS Growth | — |
| Revenue Growth | 7.80% | Earnings | 2026-04-30 | ROA | -5.46% |
| ROE | -36.21% | ROIC | — | Gross Margin | 72.73% |
| Oper. Margin | 4.07% | Profit Margin | -15.12% | Shs Outstand | 242.97M |
| Shs Float | 222.57M | Short Float | 8.64% | Short Ratio | 2.93 |
| Short Interest | — | 52W High | 8.40 | 52W Low | 3.21 |
| Beta | 0.58 | Avg Volume | 4.36M | Volume | 1.35M |
| Target Price | $16.10 | Recom | Strong_buy | Prev Close | $6.56 |
| Price | $6.57 | Change | 0.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.10
Mean price target
2. Current target
$6.63
Latest analyst target
3. DCF / Fair value
$0.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.63
Low
$13.00
High
$19.00
Mean
$16.10
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | reit | Wedbush | Outperform → Outperform | $19 |
| 2026-02-20 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2026-02-20 | reit | BTIG | Buy → Buy | $17 |
| 2026-01-29 | reit | BTIG | Buy → Buy | $17 |
| 2026-01-21 | main | Wedbush | Outperform → Outperform | $19 |
| 2026-01-09 | main | Citigroup | Buy → Buy | $14 |
| 2026-01-09 | up | Piper Sandler | Neutral → Overweight | $16 |
| 2026-01-09 | main | BTIG | Buy → Buy | $17 |
| 2025-11-04 | main | Piper Sandler | Neutral → Neutral | $10 |
| 2025-11-03 | main | Citigroup | Buy → Buy | $11 |
| 2025-10-31 | main | TD Cowen | Buy → Buy | $10 |
| 2025-08-06 | main | Piper Sandler | Neutral → Neutral | $9 |
| 2025-08-05 | main | Wedbush | Outperform → Outperform | $14 |
| 2025-08-05 | main | Raymond James | Outperform → Outperform | $12 |
| 2025-05-02 | main | Citigroup | Buy → Buy | $10 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $15 |
| 2025-02-21 | reit | Raymond James | Strong Buy → Strong Buy | $13 |
| 2025-02-21 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2025-01-27 | main | Piper Sandler | Neutral → Neutral | $8 |
| 2025-01-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
- Williams Laura a, chief patient officer, sells ARDX stock for $47803 - Investing.com ue, 24 Feb 2026 02
- ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits ue, 24 Feb 2026 05
- Millions of women suffer IBS-C in silence; LPGA and Ardelyx team up - Stock Titan ue, 24 Feb 2026 13
- Ardelyx gains after insider purchase (update) (ARDX:NASDAQ) - Seeking Alpha ue, 24 Feb 2026 14
- Susan Hohenleitner Sells 2,033 Shares of Ardelyx (NASDAQ:ARDX) Stock - MarketBeat ue, 24 Feb 2026 02
- Insider Purchase: Director at $ARDX Buys 333,333 Shares - Quiver Quantitative ue, 24 Feb 2026 02
- Ardelyx (ARDX) Price Target Increased by 10.08% to 16.20 - Nasdaq Wed, 25 Feb 2026 20
- Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update - simplywall.st ue, 24 Feb 2026 09
- Ardelyx, Inc. (ARDX) Stock Analysis: A Biotech Gem With 118% Upside Potential - DirectorsTalk Interviews Fri, 20 Feb 2026 22
- Hohenleitner Susan, Ardelyx CFO, sells $11.9k in ARDX stock - Investing.com ue, 24 Feb 2026 02
- Insider Stock Purchases: February 24, 2026 - Quiver Quantitative ue, 24 Feb 2026 18
- Ardelyx stock falls after Q1 print on outlook (ARDX:NASDAQ) - Seeking Alpha Fri, 20 Feb 2026 17
- Ardelyx (NASDAQ:ARDX) Insider James Parker Brady Sells 2,543 Shares - MarketBeat ue, 24 Feb 2026 02
- New patent shields Ardelyx gut drugs IBSRELA, XPHOZAH until 2042 - Stock Titan ue, 03 Feb 2026 08
- ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits Fri, 20 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 41666 | 260621 | — | Sale at price 6.26 per share. | RAAB MICHAEL G | Chief Executive Officer | — | 2026-02-24 00:00:00 | D |
| 1 | 20833 | 20625 | — | Conversion of Exercise of derivative security at price 0.99 per share. | RAAB MICHAEL G | Chief Executive Officer | — | 2026-02-24 00:00:00 | D |
| 2 | 45982 | 268841 | — | Sale at price 5.70 - 5.86 per share. | RAAB MICHAEL G | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
| 3 | 3179 | 18586 | — | Sale at price 5.70 - 5.86 per share. | BISHOP JOHN E | Chief Operating Officer | — | 2026-02-20 00:00:00 | D |
| 4 | 8176 | 47803 | — | Sale at price 5.71 - 5.86 per share. | WILLIAMS LAURA A | Officer | — | 2026-02-20 00:00:00 | D |
| 5 | 9595 | 56099 | — | Sale at price 5.70 - 5.86 per share. | KELLIHER MICHAEL | Officer | — | 2026-02-20 00:00:00 | D |
| 6 | 10439 | 61034 | — | Sale at price 5.70 - 5.86 per share. | FOSTER ERIC DUANE | Officer | — | 2026-02-20 00:00:00 | D |
| 7 | 2543 | 14868 | — | Sale at price 5.71 - 5.86 per share. | BRADY JAMES PARKER | Officer | — | 2026-02-20 00:00:00 | D |
| 8 | 2033 | 11886 | — | Sale at price 5.71 - 5.86 per share. | HOHENLEITNER SUSAN | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 9 | 333333 | 1946331 | — | Purchase at price 5.84 per share. | MOTT DAVID M | Director | — | 2026-02-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -16.71M | -55.35M | -60.98M | -150.85M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -39.14M | -66.07M | -67.21M | -158.16M |
| ReconciledDepreciation | 2.06M | 1.29M | 1.14M | 2.81M |
| ReconciledCostOfRevenue | 50.56M | 17.80M | 4.12M | 1.00M |
| EBITDA | -16.71M | -55.35M | -60.98M | -150.85M |
| EBIT | -18.78M | -56.65M | -62.13M | -153.66M |
| NetInterestIncome | -20.09M | -8.87M | -5.07M | -4.50M |
| InterestExpense | 20.09M | 8.87M | 5.07M | 4.50M |
| NormalizedIncome | -39.14M | -66.07M | -67.21M | -158.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -39.14M | -66.07M | -67.21M | -158.16M |
| TotalExpenses | 361.56M | 187.73M | 115.92M | 164.44M |
| TotalOperatingIncomeAsReported | -27.95M | -63.28M | -63.76M | -154.35M |
| DilutedAverageShares | 235.23M | 219.33M | 158.69M | 104.21M |
| BasicAverageShares | 235.23M | 219.33M | 158.69M | 104.21M |
| DilutedEPS | -0.17 | -0.30 | -0.42 | -1.52 |
| BasicEPS | -0.17 | -0.30 | -0.42 | -1.52 |
| DilutedNIAvailtoComStockholders | -39.14M | -66.07M | -67.21M | -158.16M |
| NetIncomeCommonStockholders | -39.14M | -66.07M | -67.21M | -158.16M |
| NetIncome | -39.14M | -66.07M | -67.21M | -158.16M |
| NetIncomeIncludingNoncontrollingInterests | -39.14M | -66.07M | -67.21M | -158.16M |
| NetIncomeContinuousOperations | -39.14M | -66.07M | -67.21M | -158.16M |
| TaxProvision | 266.00K | 547.00K | 8.00K | 4.00K |
| PretaxIncome | -38.87M | -65.52M | -67.20M | -158.16M |
| OtherIncomeExpense | 9.17M | 6.63M | 1.63M | 687.00K |
| OtherNonOperatingIncomeExpenses | 9.17M | 6.63M | 1.63M | 687.00K |
| NetNonOperatingInterestIncomeExpense | -20.09M | -8.87M | -5.07M | -4.50M |
| InterestExpenseNonOperating | 20.09M | 8.87M | 5.07M | 4.50M |
| OperatingIncome | -27.95M | -63.28M | -63.76M | -154.35M |
| OperatingExpense | 311.01M | 169.94M | 111.80M | 163.44M |
| ResearchAndDevelopment | 52.32M | 35.54M | 35.20M | 91.14M |
| SellingGeneralAndAdministration | 258.69M | 134.40M | 76.60M | 72.30M |
| GeneralAndAdministrativeExpense | 76.60M | 72.30M | ||
| OtherGandA | 76.60M | 72.30M | ||
| GrossProfit | 283.06M | 106.66M | 48.04M | 9.10M |
| CostOfRevenue | 50.56M | 17.80M | 4.12M | 1.00M |
| TotalRevenue | 333.62M | 124.46M | 52.16M | 10.10M |
| OperatingRevenue | 333.62M | 124.46M | 52.16M | 10.10M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 238.02M | 232.45M | 198.58M | 130.18M |
| ShareIssued | 238.02M | 232.45M | 198.58M | 130.18M |
| NetDebt | 85.92M | 28.35M | ||
| TotalDebt | 153.44M | 55.98M | 36.46M | 45.50M |
| TangibleBookValue | 173.29M | 166.82M | 98.33M | 82.62M |
| InvestedCapital | 324.14M | 216.64M | 125.04M | 114.88M |
| WorkingCapital | 278.62M | 195.72M | 88.00M | 80.83M |
| NetTangibleAssets | 173.29M | 166.82M | 98.33M | 82.62M |
| CapitalLeaseObligations | 2.58M | 6.16M | 9.75M | 13.24M |
| CommonStockEquity | 173.29M | 166.82M | 98.33M | 82.62M |
| TotalCapitalization | 324.14M | 216.64M | 98.33M | 82.62M |
| TotalEquityGrossMinorityInterest | 173.29M | 166.82M | 98.33M | 82.62M |
| StockholdersEquity | 173.29M | 166.82M | 98.33M | 82.62M |
| GainsLossesNotAffectingRetainedEarnings | 57.00K | 224.00K | -54.00K | -6.00K |
| OtherEquityAdjustments | 57.00K | 224.00K | -54.00K | -6.00K |
| RetainedEarnings | -885.34M | -846.20M | -780.14M | -712.93M |
| AdditionalPaidInCapital | 1.06B | 1.01B | 878.50M | 795.54M |
| CapitalStock | 24.00K | 23.00K | 20.00K | 13.00K |
| CommonStock | 24.00K | 23.00K | 20.00K | 13.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 262.46M | 130.76M | 91.74M | 67.30M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 184.63M | 80.37M | 26.13M | 14.47M |
| NonCurrentDeferredLiabilities | 32.76M | 28.82M | 20.28M | 4.73M |
| NonCurrentDeferredRevenue | 7.23M | 8.64M | 9.03M | 4.73M |
| LongTermDebtAndCapitalLeaseObligation | 151.88M | 51.55M | 5.86M | 9.75M |
| LongTermCapitalLeaseObligation | 1.02M | 1.73M | 5.86M | 9.75M |
| LongTermDebt | 150.85M | 49.82M | ||
| CurrentLiabilities | 77.83M | 50.39M | 65.60M | 52.82M |
| OtherCurrentLiabilities | 8.76M | 4.88M | 2.54M | 1.17M |
| CurrentDeferredLiabilities | 10.69M | 7.18M | 4.21M | 0.00 |
| CurrentDeferredRevenue | 10.69M | 7.18M | 4.21M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 1.56M | 4.43M | 30.61M | 35.76M |
| CurrentCapitalLeaseObligation | 1.56M | 4.43M | 3.89M | 3.49M |
| CurrentDebt | 26.71M | 32.26M | ||
| OtherCurrentBorrowings | 26.71M | 32.26M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 14.94M | 12.60M | 7.55M | 5.42M |
| PayablesAndAccruedExpenses | 41.88M | 21.30M | 20.70M | 10.47M |
| CurrentAccruedExpenses | 25.89M | 10.16M | 9.84M | 6.19M |
| InterestPayable | 203.00K | |||
| Payables | 16.00M | 11.14M | 10.86M | 4.28M |
| AccountsPayable | 16.00M | 11.14M | 10.86M | 4.28M |
| TotalAssets | 435.75M | 297.58M | 190.07M | 149.91M |
| TotalNonCurrentAssets | 79.30M | 51.47M | 36.46M | 16.26M |
| OtherNonCurrentAssets | 75.43M | 40.63M | 25.95M | 1.15M |
| NonCurrentPrepaidAssets | 0.00 | 4.24M | 0.00 | |
| InvestmentsAndAdvances | 0.00 | |||
| NetPPE | 3.88M | 6.60M | 10.52M | 15.11M |
| AccumulatedDepreciation | -10.62M | -10.20M | -9.66M | -15.89M |
| GrossPPE | 14.49M | 16.80M | 20.18M | 31.00M |
| Leases | 9.14M | 8.73M | 8.74M | 8.74M |
| OtherProperties | 2.43M | 5.63M | 9.34M | 20.23M |
| MachineryFurnitureEquipment | 2.92M | 2.43M | 2.09M | 2.03M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 356.45M | 246.11M | 153.60M | 133.65M |
| OtherCurrentAssets | 11.10M | 8.41M | 5.11M | 7.05M |
| PrepaidAssets | 16.38M | 18.93M | 13.57M | 9.41M |
| Inventory | 21.17M | 12.45M | 3.28M | 0.00 |
| Receivables | 57.70M | 22.03M | 7.73M | 502.00K |
| AccountsReceivable | 57.70M | 22.03M | 7.73M | 502.00K |
| CashCashEquivalentsAndShortTermInvestments | 250.10M | 184.30M | 123.91M | 116.69M |
| OtherShortTermInvestments | 185.17M | 162.83M | 27.77M | 44.26M |
| CashAndCashEquivalents | 64.93M | 21.47M | 96.14M | 72.43M |
| CashEquivalents | 48.65M | 18.64M | 84.31M | 71.17M |
| CashFinancial | 16.28M | 2.83M | 11.83M | 1.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -45.82M | -90.06M | -70.10M | -154.42M |
| RepaymentOfDebt | 0.00 | 0.00 | -33.04M | -19.44M |
| IssuanceOfDebt | 99.45M | 22.39M | 26.97M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 119.24M | 71.62M | 101.15M |
| CapitalExpenditure | -1.01M | -344.00K | -55.00K | -1.87M |
| InterestPaidSupplementalData | 11.41M | 4.24M | 2.90M | 3.47M |
| IncomeTaxPaidSupplementalData | 266.00K | 51.00K | 6.00K | 4.00K |
| EndCashPosition | 64.93M | 21.47M | 96.14M | 72.43M |
| BeginningCashPosition | 21.47M | 96.14M | 72.43M | 91.03M |
| ChangesInCash | 43.46M | -74.67M | 23.71M | -18.60M |
| FinancingCashFlow | 106.59M | 146.29M | 75.34M | 83.00M |
| CashFlowFromContinuingFinancingActivities | 106.59M | 146.29M | 75.34M | 83.00M |
| NetOtherFinancingCharges | -1.00M | 3.50M | 9.58M | -106.00K |
| ProceedsFromStockOptionExercised | 8.14M | 1.17M | 202.00K | 1.40M |
| NetCommonStockIssuance | 0.00 | 119.24M | 71.62M | 101.15M |
| CommonStockIssuance | 0.00 | 119.24M | 71.62M | 101.15M |
| NetIssuancePaymentsOfDebt | 99.45M | 22.39M | -6.07M | -19.44M |
| NetLongTermDebtIssuance | 99.45M | 22.39M | -6.07M | -19.44M |
| LongTermDebtPayments | 0.00 | 0.00 | -33.04M | -19.44M |
| LongTermDebtIssuance | 99.45M | 22.39M | 26.97M | 0.00 |
| InvestingCashFlow | -18.32M | -131.25M | 18.41M | 50.95M |
| CashFlowFromContinuingInvestingActivities | -18.32M | -131.25M | 18.41M | 50.95M |
| NetInvestmentPurchaseAndSale | -17.31M | -130.90M | 16.67M | 52.81M |
| SaleOfInvestment | 177.85M | 84.32M | 67.00M | 125.55M |
| PurchaseOfInvestment | -195.16M | -215.22M | -50.33M | -72.73M |
| NetPPEPurchaseAndSale | -1.01M | -344.00K | 1.74M | -1.87M |
| SaleOfPPE | 0.00 | 0.00 | 1.80M | 0.00 |
| PurchaseOfPPE | -1.01M | -344.00K | -55.00K | -1.87M |
| OperatingCashFlow | -44.81M | -89.72M | -70.04M | -152.55M |
| CashFlowFromContinuingOperatingActivities | -44.81M | -89.72M | -70.04M | -152.55M |
| ChangeInWorkingCapital | -49.17M | -43.39M | -19.57M | -11.92M |
| ChangeInOtherWorkingCapital | 2.09M | 2.59M | 8.51M | 550.00K |
| ChangeInOtherCurrentLiabilities | -4.59M | -3.93M | -3.49M | -2.85M |
| ChangeInPayablesAndAccruedExpense | 28.46M | 9.02M | 12.85M | -213.00K |
| ChangeInAccruedExpense | 23.60M | 8.74M | 6.26M | 1.14M |
| ChangeInPayable | 4.86M | 279.00K | 6.58M | -1.35M |
| ChangeInAccountPayable | 4.86M | 279.00K | 6.58M | -1.35M |
| ChangeInPrepaidAssets | 2.24M | -15.63M | -1.86M | -8.90M |
| ChangeInInventory | -41.70M | -21.14M | -28.35M | 0.00 |
| ChangeInReceivables | -35.67M | -14.30M | -7.23M | -502.00K |
| ChangesInAccountReceivables | -35.67M | -14.30M | -7.23M | -502.00K |
| OtherNonCashItems | 4.05M | 4.91M | 6.10M | 2.69M |
| StockBasedCompensation | 37.38M | 13.53M | 10.75M | 12.04M |
| AmortizationOfSecurities | 488.00K | |||
| DepreciationAmortizationDepletion | 2.06M | 1.29M | 1.14M | 2.81M |
| DepreciationAndAmortization | 2.06M | 1.29M | 1.14M | 2.81M |
| Depreciation | 1.44M | |||
| OperatingGainsLosses | -1.26M | -678.00K | ||
| GainLossOnInvestmentSecurities | 583.00K | -678.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -1.26M | 0.00 |
| NetIncomeFromContinuingOperations | -39.14M | -66.07M | -67.21M | -158.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARDX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|